Spotlight on Gastroenterology

Credits: 0.25 CME
Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD
Leonard H. Calabrese, DO
Vindico

Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.

Activity Description

In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Benjamin L. Cohen, MD, MAS
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie


Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.

Activity Description

In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Benjamin L. Cohen, MD, MAS
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie


Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Gastroenterology Presentations

0.50 CME
AKH Inc., Advancing Knowledge in Healthcare
HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application

HER2 Testing in Gastric Cancer: A Survival Guide to Interpretation and Application

Start

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: April 2, 2021
Expires: April 1, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess current HER2 testing recommendations and strategies for gastric cancer
  • Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
  • Identify current and emerging HER2-directed therapies for gastric cancer

Activity Description

In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.

Statement of Educational Need

HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.

Activity Chair

Richard Kim, MD
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL

Faculty

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL


Laura H. Tang, MD, PhD
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).

Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).

Laura H. Tang, MD, PhD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: April 2, 2021
Expires: April 1, 2022
30 minutes to complete

Provided By

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC.

Target Audience

Oncology clinicians and other healthcare professionals who diagnose and/or manage patients with gastric cancer.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Assess current HER2 testing recommendations and strategies for gastric cancer
  • Apply optimal testing and interpretation strategies to identify patients with gastric cancer that could benefit from HER2-directed therapy
  • Identify current and emerging HER2-directed therapies for gastric cancer

Activity Description

In this activity, a panel of experts discuss current methods for determining the HER2 status of gastric adenocarcinomas and/or gastroesophageal junction cancers and the implications of these findings on treatment selection in the first-line setting and beyond.

Statement of Educational Need

HER2 testing volume has been found to be significantly lower in community-based centers than academic settings. Given the rapidly changing landscape of HER2 targeted therapy for the treatment of gastric cancer, it is essential to narrow the knowledge and testing gaps among clinicians who manage individuals with gastric adenocarcinomas or gastroesophageal cancers.

Activity Chair

Richard Kim, MD
Service Chief and Senior Staff, Gastrointestinal Oncology
H. Lee Moffitt Cancer Center
Professor, University of South Florida
Tampa, FL

Faculty

Daniel Catenacci, MD
Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
University of Chicago Medical Center
Chicago, IL


Laura H. Tang, MD, PhD
Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor, Pathology
Will Cornell Medical College
New York, NY

Conflict of Interest Policy/Disclosure Statement

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Richard Kim, MD, has affiliations with BMS, Lilly (Consultant); Bayer, BMS, Eisai (Contracted Research); Incyte (Speakers Bureau).

Daniel Catenacci, MD, has affiliations withAmgen, Archer & Natera, Astellas, BMS, Daiichi Sankyo, Lilly, Five Prime, Foundation Medicine, Guardant Health, Genentech/Roche, Gritstone, Merck, Pieris, QED, Taiho, Tempus, Zymeworks (Consultant); Genentech/Roche, Guardant Health, Lilly, Merck, Tempus (Speakers Bureau).

Laura H. Tang, MD, PhD, has no financial relationships to disclose.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

AKH Staff and Planners
Dorothy Caputo, MA, BSN, RN, AKH Lead Nurse Planner/Reviewer, has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations/Reviewer, has no financial relationships to disclose.
AKH Inc. planners and reviewers disclosed no financial relationships.

RMEI Medical Education, LLC
Kim Farina, PhD, Medical Writer, has no financial relationships to disclose.
Sharon Powell, Senior Medical Editor, has no financial relationships to disclose.
Kirk A. Tacka, PhD, Medical Writer, has no financial relationships to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosure
It is the policy of AKH Inc. and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. and RMEI Medical Education, LLC specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Accreditation Statement

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Fee Information
There is no fee for this educational activity.

Criteria For Success
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 70% or higher on the post-test to receive credit for this activity.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.

0.75 CME
Vindico
Harnessing Immunological Pathways to Improve the Treatment of Moderate to Severe Crohn's Disease

Harnessing Immunological Pathways to Improve the Treatment of Moderate to Severe Crohn's Disease

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with moderate to severe Crohn’s disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
  • Assess new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe Crohn’s disease.

Activity Description

Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors—all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.

Agenda

Targeting Immunological Pathways in CD
Bruce E. Sands, MD, MS

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe CD
Jessica R. Allegretti, MD, MPH; William J. Sandborn, MD

Activity Chair

William J. Sandborn, MD
Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA

Disclosures:
Consulting Fee: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead, Gossamer Bio, Incyte, Janssen, Kyowa Kirin, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Seres, Shire, Sienna Biopharmaceuticals, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, TiGenix, Tillotts, UCB, Ventyx, Vimalan Biosciences, Vivelix
Contracted Research: AbbVie, Amgen, Atlantic Healthcare, Celgene/Receptos, Genentech, Gilead, Janssen, Lilly, Pfizer, Prometheus, Takeda
Ownership Interest: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Progenity, Prometheus, Ritter, Shoreline, Ventyx, Vimalan Biosciences

Faculty

Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:
Consulting Fee: Artugen, Bacainn, Finch Therapeutics, Iterative Scopes, Janssen, Morphic Therapeutic, Pandion, Pfizer, Salix, Servatus, Takeda
Contracted Research: Merck


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY

Disclosures:
Consulting Fee: Abivax, Arena Pharmaceuticals, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, Celltrion, Genentech, Gilead, GlaxoSmithKline, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kallyope, Pfizer, Prometheus, Protagonist Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, Viela Bio

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at: CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: March 31, 2021
Expires: March 30, 2022
45 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists and other health care professionals involved in the management of patients with moderate to severe Crohn’s disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Describe emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.
  • Assess new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe Crohn’s disease.

Activity Description

Crohn’s disease (CD) is a chronic, progressive, idiopathic inflammatory disorder that can affect any component of the gastrointestinal tract. Approximately 780,000 individuals in the United States have CD, with the incidence and prevalence increasing worldwide. The ongoing clinical evaluation of emerging therapies with unique mechanisms of action holds promise for a more optimal disease response. Over the past 20 years, biologic agents have redefined the management of moderate to severe CD. Agents that impact not only clinical response and remission but also mucosal healing are now of paramount interest. Available biologic therapies for CD include anti–tumor necrosis factor-α agents, an integrin inhibitor, and interleukin 12/23 inhibitors—all of which are administered either intravenously or subcutaneously. Several oral small-molecule therapies are also under investigation for the treatment of moderate to severe CD, including Janus kinase protein inhibitors. Oral agents that modulate sphingosine 1-phosphate, which guides lymphocyte circulation through secondary lymphoid organs such as the spleen and lymph nodes, are being studied as well. In this CME activity, experts summarize new evidence on investigational agents with unique mechanisms of action that are in late-stage development for treating moderate to severe CD. The most recent clinical findings on the safety and efficacy of therapies targeting immunological pathways are also evaluated.

Agenda

Targeting Immunological Pathways in CD
Bruce E. Sands, MD, MS

How Emerging Agents are Performing in Safety and Efficacy in Moderate to Severe CD
Jessica R. Allegretti, MD, MPH; William J. Sandborn, MD

Activity Chair

William J. Sandborn, MD
Distinguished Professor of Medicine
Chief, Division of Gastroenterology
Director, UCSD IBD Center
UC San Diego Health System
La Jolla, CA

Disclosures:
Consulting Fee: AbbVie, Alimentiv, Allergan, Amgen, Arena Pharmaceuticals, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead, Gossamer Bio, Incyte, Janssen, Kyowa Kirin, Landos, Lilly, Oppilan, Otsuka, Pfizer, Progenity, Prometheus, Reistone, Seres, Shire, Sienna Biopharmaceuticals, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance, TiGenix, Tillotts, UCB, Ventyx, Vimalan Biosciences, Vivelix
Contracted Research: AbbVie, Amgen, Atlantic Healthcare, Celgene/Receptos, Genentech, Gilead, Janssen, Lilly, Pfizer, Prometheus, Takeda
Ownership Interest: BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan, Progenity, Prometheus, Ritter, Shoreline, Ventyx, Vimalan Biosciences

Faculty

Jessica R. Allegretti, MD, MPH
Associate Director, Crohn’s and Colitis Center
Brigham and Women’s Hospital
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:
Consulting Fee: Artugen, Bacainn, Finch Therapeutics, Iterative Scopes, Janssen, Morphic Therapeutic, Pandion, Pfizer, Salix, Servatus, Takeda
Contracted Research: Merck


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY

Disclosures:
Consulting Fee: Abivax, Arena Pharmaceuticals, Bacainn Therapeutics, Boston Pharmaceuticals, Calibr, Celltrion, Genentech, Gilead, GlaxoSmithKline, Index Pharmaceuticals, Inotrem, Ironwood Pharmaceuticals, Janssen, Kallyope, Pfizer, Prometheus, Protagonist Therapeutics, Surrozen, Takeda, Target RWE, USWM Enterprises, Viela Bio

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at: CME@VindicoCME.com

1.00 CME
AcademicCME
Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Advances in Sphingosine-1-phosphate (S1P) Therapeutics to Improve Outcomes in Patients with Inflammatory Bowel Disease

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, physician assistants and other healthcare providers who care for patients with IBD.

Learning Objectives

  1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to reduce inflammation in patients with IBD
  2. Analyze ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with IBD
  3. Develop treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes

Activity Description

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how S1P receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and efficacy of novel S1P therapeutics to treat patients with IBD will be reviewed and analyzed. The faculty will also delve into treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes. Upon completion of this educational program, clinicians will gain better insight into how to better manage their patients with inflammatory bowel disease by utilizing S1P therapeutics.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with inflammatory bowel disease.

Agenda

  1. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for IBD
  2. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Crohn’s Disease and Ulcerative Colitis Disease
  3. Treatment Strategies for the Application of S1P Therapeutics to Optimize IBD Patient Outcomes

Faculty

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA


Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH


David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

William J. Sandborn, MD (Course Chair)

Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb Company; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc.; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics; Surrozen; Takeda Pharmaceutical Company; Theravance Biopharma; Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma

Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc.

Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.

Miguel Regueiro, MD

Consultant/Advisor: Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB

Grant/Research Support:AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company

David T. Rubin, MD

Consultant/Advisor: AbbVie Inc.; AbGenomics International, Inc.; Allergan; Biomica; Boehringer Ingelheim; Bristol Meyers Squibb Company; CDx Diagnostics; Check-Cap; Dizal Pharma; Eli Lilly and Company; Galen Limited; Genentech USA, Inc.; Gilead Sciences, Inc.; Ichnos Sciences S.A.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated.
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 2, 2020
Expires: December 1, 2021
60 minutes to complete

Accredited By

Target Audience

Gastroenterologists, physician assistants and other healthcare providers who care for patients with IBD.

Learning Objectives

  1. Understand the sphingosine-1-phosphate (S1P) receptor modulator as a therapeutic target to reduce inflammation in patients with IBD
  2. Analyze ongoing clinical trials for the efficacy and safety of novel S1P therapeutics to treat patients with IBD
  3. Develop treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes

Activity Description

This CME activity will highlight advances in sphinogosine-1-phosphate (S1P) therapeutics to improve outcomes in patients with inflammatory bowel disease. The expert faculty, led by Dr. William Sandborn, will discuss how S1P receptor modulators are utilized as a therapeutic target to reduce inflammation in patients with inflammatory bowel disease (IBD). Recent and emerging clinical trial data on the safety and efficacy of novel S1P therapeutics to treat patients with IBD will be reviewed and analyzed. The faculty will also delve into treatment strategies for the application of S1P therapeutics to optimize IBD patient outcomes. Upon completion of this educational program, clinicians will gain better insight into how to better manage their patients with inflammatory bowel disease by utilizing S1P therapeutics.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with inflammatory bowel disease.

Agenda

  1. Scientific Update for Sphingosine-1-Phosphate (S1P) Receptor Modulators as a Therapeutic Target for IBD
  2. A Clinical Trial Review and Analysis on the Safety and Efficacy of Novel S1P Therapeutics for the Management of Crohn’s Disease and Ulcerative Colitis Disease
  3. Treatment Strategies for the Application of S1P Therapeutics to Optimize IBD Patient Outcomes

Faculty

William J. Sandborn, MD
Professor and Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego
San Diego, CA


Miguel Regueiro, MD
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH


David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Co-Director, Digestive Diseases Center
University of Chicago Medicine
Chicago, IL


Conflict of Interest Policy/Disclosure Statement

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

William J. Sandborn, MD (Course Chair)

Consultant/Advisor: AbbVie Inc.; ABIVAX; Admirx; Alfasigma USA, Inc.; Alimentiv; Alivio Therapeutics; Allakos Inc.; Amgen Inc.; Applied Molecular Transpor Inc.; Arena Pharmaceuticals, Inc.; Bausch Health Companies Inc.; BeiGene; Bellatrix Pharmaceuticals; Boehringer Ingelheim; Boston Pharmaceuticals; Bristol Meyers Squibb Company; Celgene; Celltrion Healthcare Co.,Ltd.; Celularity Inc.; Cosmo Pharmaceuticals; Eli Lilly and Company; Escalier Biosciences; Equillium, Inc.; Forbion Capital Partners; Genentech USA, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals, Inc.; Gossamer Bio; Immunic Therapeutics; InDex Pharmaceuticals; Intact Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Kyverna Therapeutics, Inc.; Landos Biopharma, Inc.; Oppilan Pharma Ltd.; Otsuka America Pharmaceutical, Inc.; Pandion Therapeutics; Pfizer Inc.; Progenity, Inc.; Prometheus Biosciences; Protagonist Therapeutics; ProventionBio; Reistone Biopharma; Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics; Surrozen; Takeda Pharmaceutical Company; Theravance Biopharma; Thetis Pharmaceuticals LLC; Tillotts Pharma AG; UCB; Vedanta Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.; Vivelix Pharmaceuticals; Vivreon Biosciences; Zealand Pharma

Grant/Research Support: AbbVie Inc.; ABIVAX; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Celgene; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Seres Therapeutics; Shire LLC; Takeda Pharmaceutical Company; Theravance Biopharma, Inc.

Stocks: Allakos Inc.; BeiGene, Gossamer Bio; Oppilan Pharma Ltd; Prometheus Biosciences; Progenity; Shoreline Biosciences, Inc.; Ventyx Biosciences, Inc.; Vimalan Biosciences, Inc.

Miguel Regueiro, MD

Consultant/Advisor: Arena Pharmaceuticals, Inc.; Bristol Meyers Squibb Company; Eli Lilly and Company; Genentech USA, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Biosciences; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceutical Company; UCB

Grant/Research Support:AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company

David T. Rubin, MD

Consultant/Advisor: AbbVie Inc.; AbGenomics International, Inc.; Allergan; Biomica; Boehringer Ingelheim; Bristol Meyers Squibb Company; CDx Diagnostics; Check-Cap; Dizal Pharma; Eli Lilly and Company; Galen Limited; Genentech USA, Inc.; Gilead Sciences, Inc.; Ichnos Sciences S.A.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Narrow River Management; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; Takeda Pharmaceutical Company; Techlab, Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated.
  6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Bristol Myers Squibb Company.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.25 CME
Vindico
Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD

Immune-Mediated Inflammatory Disease Curbside Consults: Updates in Non-TNF Biologic Options for Patients With IBD

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.

Activity Description

In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Benjamin L. Cohen, MD, MAS
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie


Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: October 19, 2020
Expires: October 18, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.

Learning Objective

Upon successful completion of this activity, participants should be better able to examine the latest clinical safety and efficacy of available and emerging non-tumor necrosis factor biologics for the management of patients with inflammatory bowel disease.

Activity Description

In this Curbside Consult video, Drs. Miguel Regueiro and Benjamin Cohen discuss the clinical evidence to support emerging treatment options for a patient with biologic-naïve Crohn’s disease.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB


Faculty

Benjamin L. Cohen, MD, MAS
Co-Section Head and Clinical Director for Inflammatory Bowel Disease
Cleveland Clinic
Cleveland, OH

Disclosures:
Consulting Fee: AbbVie, Sublimity Therapeutics, Target PharmaSolutions
Contracted Research: AbbVie


Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH

Disclosures:
Royalties: Wolters Kluwer Health/UpToDate
Consulting Fee: AbbVie, Allergan, Amgen, Celgene, Genentech, Gilead, Janssen, Lilly, Miraca Labs, Pfizer, Prometheus, Salix, Seres, Takeda, Target PharmaSolutions, UCB
Contracted Research: AbbVie, Janssen, Pfizer, Takeda


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com.

1.50 CME
Vindico
Targeting Immunological Pathways in Moderate to Severe Ulcerative Colitis

Targeting Immunological Pathways in Moderate to Severe Ulcerative Colitis

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: August 12, 2020
Expires: August 11, 2021
90 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists, advanced practice providers, and other health care professionals involved in the management of patients with ulcerative colitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest evidence about investigational agents with unique mechanisms of action in late-stage development for the treatment of moderate to severe ulcerative colitis.
  • Evaluate new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe ulcerative colitis.
  • Compare therapeutic regimens for moderate to severe ulcerative colitis in terms of their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve, as well as those who have received TNF inhibitors.

Activity Description

Faculty review the latest evidence about investigational agents with unique mechanisms of action in late-stage development for ulcerative colitis (UC) and evaluate new clinical data on the efficacy and safety of therapeutic agents that target the immunological pathways of UC.

Agenda

Introduction and Current State of Moderate to Severe UC
Stephen B. Hanauer, MD

Targeting Immunological Pathways in Moderate to Severe UC
Bruce E. Sands, MD, MS

Comparative Analysis – Safety and Efficacy of Emerging Agents in Treatment-naïve and Treatment-experienced Patients
Christina Y. Ha, MD, FACG, AGAF

Case Presentation and Summary
Stephen B. Hanauer, MD

Activity Chair

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL
Disclosures:
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, TiGenix, UCB Pharma, VHsquared
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Data and Safety Monitoring Board: Arena Pharmaceuticals, Bristol-Myers Squibb

Faculty

Christina Y. Ha, MD, FACG, AGAF
Associate Professor of Medicine
Inflammatory Bowel Disease Center
Cedars-Sinai
Los Angeles, CA
Disclosures:
Consulting Fee: AbbVie, Genentech, IBD Remedy, Imedex, Janssen, Pfizer, Prova Education, Salix, Takeda
Speakers Bureau: AbbVie


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY
Disclosures:
Consulting Fee: AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, F. Hoffmann-La Roche AG, Immunic AG, Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan, OSE Immunotherapeutics, Otsuka, Pfizer, Prometheus, RedHill Biopharma, Shire, Takeda, Target PharmaSolutions, Theravance


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.  

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 12, 2020 to August 11, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: August 12, 2020
Expires: August 11, 2021
90 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is gastroenterologists, advanced practice providers, and other health care professionals involved in the management of patients with ulcerative colitis.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Assess the latest evidence about investigational agents with unique mechanisms of action in late-stage development for the treatment of moderate to severe ulcerative colitis.
  • Evaluate new clinical data on the efficacy and safety of therapeutics that target immunological pathways in the treatment of moderate to severe ulcerative colitis.
  • Compare therapeutic regimens for moderate to severe ulcerative colitis in terms of their ability to improve outcomes in patients who are tumor necrosis factor (TNF) inhibitor-naïve, as well as those who have received TNF inhibitors.

Activity Description

Faculty review the latest evidence about investigational agents with unique mechanisms of action in late-stage development for ulcerative colitis (UC) and evaluate new clinical data on the efficacy and safety of therapeutic agents that target the immunological pathways of UC.

Agenda

Introduction and Current State of Moderate to Severe UC
Stephen B. Hanauer, MD

Targeting Immunological Pathways in Moderate to Severe UC
Bruce E. Sands, MD, MS

Comparative Analysis – Safety and Efficacy of Emerging Agents in Treatment-naïve and Treatment-experienced Patients
Christina Y. Ha, MD, FACG, AGAF

Case Presentation and Summary
Stephen B. Hanauer, MD

Activity Chair

Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Northwestern University Feinberg School of Medicine
Medical Director, Digestive Health Center
Chicago, IL
Disclosures:
Consulting Fee: AbbVie, Allergan, Amgen, Arena Pharmaceuticals, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Nestle, Novartis, Pfizer, Progenity, Prometheus, Receptos, Salix, Samsung Bioepis, Seres Therapeutics, Takeda, TiGenix, UCB Pharma, VHsquared
Speakers Bureau: AbbVie, Janssen, Takeda
Contracted Research: (paid to institution): AbbVie, Allergan, Amgen, Celgene, Genentech, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Prometheus, Receptos, Takeda, UCB Pharma
Data and Safety Monitoring Board: Arena Pharmaceuticals, Bristol-Myers Squibb

Faculty

Christina Y. Ha, MD, FACG, AGAF
Associate Professor of Medicine
Inflammatory Bowel Disease Center
Cedars-Sinai
Los Angeles, CA
Disclosures:
Consulting Fee: AbbVie, Genentech, IBD Remedy, Imedex, Janssen, Pfizer, Prova Education, Salix, Takeda
Speakers Bureau: AbbVie


Bruce E. Sands, MD, MS
Chief, Dr. Henry D. Janowitz Division of Gastroenterology
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai Hospital and Mount Sinai Health System
New York, NY
Disclosures:
Consulting Fee: AbbVie, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion, Genentech, F. Hoffmann-La Roche AG, Immunic AG, Ironwood Pharmaceuticals, Janssen, Lilly, Morphic Therapeutic, Oppilan, OSE Immunotherapeutics, Otsuka, Pfizer, Prometheus, RedHill Biopharma, Shire, Takeda, Target PharmaSolutions, Theravance


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education Staff:
No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.  

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 12, 2020 to August 11, 2021.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com

0.75 CME
Integrity Continuing Education, Inc.
The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH

The Dawn of a New Era: Emerging Therapeutic Strategies in the Diagnosis and Management of NASH

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 1, 2020
Expires: July 1, 2021
45 minutes to complete

Accredited By

Target Audience

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Learning Objectives

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for nonalcoholic fatty liver disease (NAFLD)/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH

Activity Description

NAFLD affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. NASH, the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression. There is currently no FDA-approved targeted treatment for NASH. However, promising agents are undergoing late-stage clinical trials, and providers must be brought up-to-date on recent safety and efficacy outcomes. Barriers to clinical trial enrollment must also be addressed. Understanding the disease pathophysiology that informs drug development will aid in applying these agents to practice should FDA approval be obtained. This educational activity will address these knowledge gaps among healthcare providers involved in the care of patients with NASH, and application of the knowledge gained will improve patient outcomes.

Faculty

Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven L. Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Intercept Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 1, 2020
Expires: July 1, 2021
45 minutes to complete

Accredited By

Target Audience

This educational activity addresses the needs of gastroenterologists, hepatologists, and other healthcare professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Learning Objectives

  • Employ current epidemiologic and demographic data to enhance NASH identification
  • Apply liver biopsy and complementary noninvasive modalities for nonalcoholic fatty liver disease (NAFLD)/NASH diagnosis, staging, and monitoring
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Discuss the safety and efficacy of emerging therapies undergoing clinical development for NASH

Activity Description

NAFLD affects 24% of the American population and is projected to be the cause of nearly 800,000 excessive liver deaths from 2015 to 2030. NASH, the aggressive form of NAFLD, is a growing cause of cirrhosis and hepatocellular carcinoma and increasingly an indicator for liver transplantation. Healthcare providers would benefit from education on current epidemiologic and demographic data to enhance NASH identification, along with information on the use of liver biopsy and complementary noninvasive modalities to diagnose, stage, and monitor NAFLD/NASH progression. There is currently no FDA-approved targeted treatment for NASH. However, promising agents are undergoing late-stage clinical trials, and providers must be brought up-to-date on recent safety and efficacy outcomes. Barriers to clinical trial enrollment must also be addressed. Understanding the disease pathophysiology that informs drug development will aid in applying these agents to practice should FDA approval be obtained. This educational activity will address these knowledge gaps among healthcare providers involved in the care of patients with NASH, and application of the knowledge gained will improve patient outcomes.

Faculty

Steven L. Flamm, MD
Professor of Medicine
Chief, Transplant Hepatology
Feinberg School of Medicine
Northwestern University
Chicago, Illinois


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven L. Flamm, MD
Consulting Fees: Intercept Pharmaceuticals
Contracted Research: Intercept Pharmaceuticals

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving CME Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 1, 2020 through July 1, 2021 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or via email at information@integrityce.com.

Statement of Commercial Support

This activity is supported by an independent educational grant from Intercept Pharmaceuticals.